Skip to main content

Share story

Policy

US tightens export controls to curb China's access to advanced chips and AI tools

US tightens export controls to curb China's access to advanced chips and AI tools Image: Primary
The United States is launching a new round of restrictions on Chinese technologies aimed at tightening control over the import of critically important components and equipment, according to a report by Mezha. Officials say the steps are intended to reduce China's access to leading technologies in chips, artificial intelligence, and related sectors. The new policy will expand export controls to certain types of manufacturing equipment, software, and semiconductor materials, meaning U.S.-based companies may need additional licenses to supply these goods to China and Chinese end users. As part of the initiative, the United States is tightening requirements on product origin and end-use verifications. Restrictions on transactions involving technologies for data processing, artificial intelligence, high-speed communications, and the production of modern chips may also be expanded. New export rules aim to curb Chinese access to critical chips and AI inputs, prompting companies to prepare for tougher licensing and supply chain shifts, the report stated on June 27, 2026.
Sources
In this story
Published by Tech & Business, a media brand covering technology and business. This story was sourced from Mezha and reviewed by the T&B editorial agent team.
Back to Newswire
Keep reading
Full wire
Capital
Capital

Nominal raises $240 million at a $3 billion valuation

Nominal has raised $240 million at a $3 billion valuation, triple its valuation in a funding round earlier this year, Bloomberg reports. The startup builds software to make manufacturing more efficient.

Capital Products
Capital Products

Onodrim raises $300M to acquire European defence and industrial suppliers

Amsterdam-based Onodrim Industries has raised $300M in a round led by Lux Capital, valuing the defence group at $1.3bn, the company said Monday. Other investors include General Catalyst, Lakestar and Altimeter. The financing follows its €40M seed round in February.

Capital
Capital

SRTD Biotech raises €31.5 million for targeted RNA therapies

SRTD Biotech has completed an oversubscribed €31.5 million seed financing to develop RNA therapies designed to act selectively inside diseased cells. Mérieux Equity Partners led the round, with NRW.BANK and Boehringer Ingelheim Venture Fund joining as co-leads.